CRISPR gene-editing therapy safely reduces cholesterol and triglycerides in first-in-human trial

newsroom.heart.org

A one-time CRISPR gene-editing therapy trial showed it safely lowered cholesterol and triglycerides. The investigational treatment, CTX310, targets the ANGPTL3 gene in the liver, reducing LDL cholesterol by nearly 50% and triglycerides by about 55% within two weeks. This approach, if confirmed in larger studies, could offer a lasting alternative to daily medications for lipid disorders.


With a significance score of 6, this news ranks in the top 0.2% of today's 31158 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


CRISPR gene-editing therapy safely reduces cholesterol and triglycerides in first-in-human trial | News Minimalist